Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Wells Fargo has recently initiated Exact Sciences Corp (EXAS) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated the ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth quarter. The cut, which William Blair analysts called a “shocking ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. Exact Sciences said it has agreed to buy Thrive for a cash and ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

November 05, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point Exact Sciences Q3 EPS loss of $0.21 fell short of analyst ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.